E-mail a Wiley Online Library Link

Martee L. Hensley, J. Kyle Wathen, Robert G. Maki, Dejka M. Araujo, Gregory Sutton, Dennis A. Priebat, Suzanne George, Robert A. Soslow and Laurence H. Baker Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma Cancer 119

Version of Record online: 18 JAN 2013 | DOI: 10.1002/cncr.27942

Among women with high-grade, uterus-limited leiomyosarcoma who receive treatment with adjuvant gemcitabine plus docetaxel followed by doxorubicin, 78% remain progression-free at 2 years, and 57% remain progression-free at 3 years.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field